Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prostate brachytherapy: importance of technique

Autor: P D Grimm, Cavanagh W, J C Blasko, H Ragde

Publikováno v: Journal of Clinical Oncology. 14:1965-1967

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c7db224179371285cf85d16607fb11df
https://doi.org/10.1200/jco.1996.14.6.1965

Zobrazit plný text záznamu

Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone

Autor: H, Ragde, G L, Grado, B S, Nadir

Publikováno v: Archivos espanoles de urologia. 54(7)

To report 13-year biochemical disease-free survival results on 769 consecutive prostate cancer patients treated with brachytherapy alone.Seven hundred sixty-nine patients with stage T1-T3, low to high Gleason grade prostate cancer underwent transperi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8fda167f0d1e3c9bb890475868638db9
https://pubmed.ncbi.nlm.nih.gov/11692443

Zobrazit plný text záznamu

Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up

Autor: H, Ragde, L J, Korb, A A, Elgamal, G L, Grado, B S, Nadir

Publikováno v: Cancer. 89(1)

The purported lack of long term modern prostate brachytherapy outcome data continues to lead many physicians to recommend other, more traditional treatments. This concern for long term results has encouraged the authors to supplement their earlier 10

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::000c074a05cbae12c50c1f2a5defb2f9
https://pubmed.ncbi.nlm.nih.gov/10897010

Zobrazit plný text záznamu

Brachytherapy for clinically localized prostate cancer

Autor: H, Ragde, L, Korb

Publikováno v: Seminars in surgical oncology. 18(1)

Prostate brachytherapy is an effective treatment option for clinically organ-confined prostate carcinoma. Observed 5- and 10-year follow-up have documented prostate-specific antigen (PSA) levels that were comparable to published radical prostatectomy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a94644a424712b00b7ff5920e159ef7a
https://pubmed.ncbi.nlm.nih.gov/10617896

Zobrazit plný text záznamu

Follow-up evaluation of a phase II prostate cancer vaccine trial

Autor: B A, Tjoa, S J, Simmons, A, Elgamal, M, Rogers, H, Ragde, G M, Kenny, M J, Troychak, A L, Boynton, G P, Murphy

Publikováno v: The Prostate. 40(2)

A phase II trial, involving infusions of autologous dendritic cells (DC) and two human histocompatibility antigen (HLA-A2)-specific prostate-specific membrane antigen (PSMA) peptides, was recently completed. Thirty percent of the participants, includ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::db213d69aeaa4f93ae3a065a1b762c98
https://pubmed.ncbi.nlm.nih.gov/10386473

Zobrazit plný text záznamu

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

Autor: S J, Simmons, B A, Tjoa, M, Rogers, A, Elgamal, G M, Kenny, H, Ragde, M J, Troychak, A L, Boynton, G P, Murphy

Publikováno v: The Prostate. 39(4)

Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF; Leukine [sargramostim], Immunex Corp., Seattle, WA) was administered to a subgroup of 44 patients in a phase II clinical trial for prostate cancer using DC pulsed with HLA-A2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::aa05b31019e37805f850a84285790712
https://pubmed.ncbi.nlm.nih.gov/10344219

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání